|
07.01.2025 13:48:18
|
Verona Pharma Expects Preliminary Q4 Sales Of About $36 Mln From Ohtuvayre
(RTTNews) - Verona Pharma plc (VRNA), a biopharmaceutical company, Tuesday announced that the company expects preliminary unaudited fourth quarter net product sales of $36 million and full year sales of $42 million. The sales are from Ohtuvayre, that got approved by FDA in June 26, 2024.
The company expects to expand Ohtuvayre further in 2025. According to Verona, more than 3,500 unique healthcare professionals have prescribed Ohtuvayre. More than 16,000 prescriptions were filled, while approximately one-third of which were patient refills.
The company said it has raised $100 million through the sale of its ordinary shares in the form of ADSs under its 'at-the-market' equity offering program with Jefferies. The shares were sold at an average price of $39.35 per ADS, equivalent to $4.92 per ordinary share.
In the pre-market trading, VRNA is 0.69% less at $44.50 on the Nasdaq.
Analysen zu Verona Pharma PLC (spons. ADRs)
Im BX Morningcall werden folgende Aktien analysiert und erklärt:
✅ LPL Finance
✅ Blackstone
✅ Ares Management
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
| Verona Pharma PLC (spons. ADRs) | 54.83 | 1.35% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
SMI geht im Plus ins Wochenende -- DAX schliesst nach Rekordhoch über 21'500-Punkte-Marke etwas tiefer -- Hang Seng legt letztlich kräftig zuDer heimische Aktienmarkt zeigte sich am Freitag etwas höher, während der deutsche Leitindex nach neuen Rekorden ins Minus drehte. Die US-Börsen notieren schwächer. Die asiatischen Indizes zeigten sich zum Wochenausklang überwiegend freundlich.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |